{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T06:03:57Z","timestamp":1794895437511,"version":"4.9.1"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["TDNCC18K0"],"award-info":[{"award-number":["TDNCC18K0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008333","name":"University of Alabama at Birmingham","doi-asserted-by":"publisher","award":["P30DK072482"],"award-info":[{"award-number":["P30DK072482"]}],"id":[{"id":"10.13039\/100008333","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 TR004399"],"award-info":[{"award-number":["UM1 TR004399"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["TDNCC18K0"],"award-info":[{"award-number":["TDNCC18K0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"University of Alabama at Birmingham","doi-asserted-by":"publisher","award":["P30DK072482"],"award-info":[{"award-number":["P30DK072482"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 TR004399"],"award-info":[{"award-number":["UM1 TR004399"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Elexacaftor\/tezacaftor\/ivacaftor (ETI) provided substantial health benefits to children with cystic fibrosis (CF) in clinical trials; there is less information about its effectiveness in a \u201creal world\u201d setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The aim of the PROMISE (A Prospective Study to Evaluate Biological and Clinical Effects of Significantly Corrected CFTR Function) Pediatric substudy is to determine the long-term (four years) impact of clinically prescribed ETI among children 6\u201311 years of age at enrollment. The primary outcome measure is the lung clearance index at a 2.5% (LCI2.5).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The PROMISE Pediatric substudy enrolled children with CF 6 to &amp;lt;12 years of age starting ETI. Outcomes measured at baseline (before ETI) and 1, 3, 6, and 12 months after ETI initiation included LCI2.5, percentage predicted forced expiratory volume in 1 second, Cystic Fibrosis Questionnaire\u2013Revised (CFQ-R) respiratory domain symptom score, height, weight, oropharyngeal cultures, and culture and deoxyribonucleic acid\u2013based analysis of sputum microbiology (when sputum was available). Sweat chloride was assessed at baseline and at 1 and 6 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>One hundred twenty-five participants were enrolled at 20 U.S. CF centers. Lung function improvement after ETI initiation was rapid and sustained through 12 months, with a mean decrease in LCI2.5 of \u22120.79 (95% confidence interval [CI], \u22121.04 to 0.55) and a mean increase in percentage predicted forced expiratory volume in 1 second of 5.6% (95% CI, 3.4% to 7.7%). Respiratory symptoms also diminished significantly (mean change in CFQ-R respiratory domain symptom score, 4.1 [95% CI, 1.94 to 6.24]). Sweat chloride decreased significantly at 6 months (mean change, \u221247.2 mmol\/L [95% CI, \u221251.99 to \u221243.8 mmol\/L]). Weight, body mass index, and height z-scores were not different from baseline at 12 months. Staphylococcus aureus prevalence in oropharyngeal or sputum cultures did not change, but its density in sputum cultures decreased a mean of 1.47 log10 colony-forming units\/g (95% CI, \u22122.37 to \u22120.58 colony-forming units\/g) at 12 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Initiation of ETI in a real-world setting was associated with clinically significant improvements in lung function and symptoms and decreased S. aureus sputum density at one year; lung function improvements were smaller than those reported in clinical trials.<\/jats:p>\n                    <jats:p>Clinical trial registered with www.clinicaltrials.gov (NCT 04038047).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1513\/annalsats.202501-103oc","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T15:01:22Z","timestamp":1750431682000},"page":"1696-1708","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":16,"title":["Clinical Effectiveness of Elexacaftor\/Tezacaftor\/Ivacaftor in 6- to 11-Year-Olds with Cystic Fibrosis: An Observational Study"],"prefix":"10.1093","volume":"22","author":[{"given":"Jessica E.","family":"Pittman","sequence":"first","affiliation":[{"name":"Department of Pediatrics, School of Medicine, Washington University, St. Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Morgan","sequence":"additional","affiliation":[{"name":"Department of Microbiology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"McCreary","sequence":"additional","affiliation":[{"name":"Cystic Fibrosis Foundation Therapeutics Development Network Coordinating Center and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuong T.","family":"Vu","sequence":"additional","affiliation":[{"name":"Cystic Fibrosis Foundation Therapeutics Development Network Coordinating Center and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0981-740X","authenticated-orcid":false,"given":"Peter","family":"Jorth","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine"},{"name":"Department of Medicine, and"},{"name":"Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonya","family":"Heltshe","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington"},{"name":"Cystic Fibrosis Foundation Therapeutics Development Network Coordinating Center and"},{"name":"Center for Respiratory Biology and Therapeutics, Seattle Children\u2019s Research Institute, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8864-6751","authenticated-orcid":false,"given":"Lucas R.","family":"Hoffman","sequence":"additional","affiliation":[{"name":"Department of Microbiology, and"},{"name":"Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington"},{"name":"Center for Respiratory Biology and Therapeutics, Seattle Children\u2019s Research Institute, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Kelly","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetes, Department of Pediatrics, Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6172-4465","authenticated-orcid":false,"given":"Scott D.","family":"Sagel","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Children\u2019s Hospital Colorado, University of Colorado Anschutz Medical Campus, Aurora, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep K.","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Microbiology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George M.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Rosenfeld","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington"},{"name":"Center for Respiratory Biology and Therapeutics, Seattle Children\u2019s Research Institute, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Ratjen","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Department of Pediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada"},{"name":"Translational Medicine, SickKids Research Institute, Toronto, Ontario, Canada; and"},{"name":"University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,1]]},"reference":[{"key":"2026020221021553300_bib1","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMra2216474","article-title":"Cystic fibrosis","volume":"389","author":"Grasemann","year":"2023","journal-title":"N Engl J Med"},{"key":"2026020221021553300_bib2","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/ppul.25285","article-title":"Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype","volume":"56","author":"McGarry","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"2026020221021553300_bib3","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A phase 3 open-label study of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020221021553300_bib4","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1164\/rccm.202202-0392OC","article-title":"Efficacy and safety of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis heterozygous for F508del and a minimal function mutation: a phase 3b, randomized, placebo-controlled study","volume":"206","author":"Mall","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020221021553300_bib5","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jcf.2021.02.003","article-title":"PROMISE: working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy","volume":"20","author":"Nichols","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2026020221021553300_bib6","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020221021553300_bib7","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s11136-011-0091-5","article-title":"Psychometric evaluation of the Cystic Fibrosis Questionnaire\u2013Revised in a national sample","volume":"21","author":"Quittner","year":"2012","journal-title":"Qual Life Res"},{"key":"2026020221021553300_bib8","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1164\/rccm.201908-1590ST","article-title":"Standardization of spirometry 2019 update: an official American Thoracic Society and European Respiratory Society technical statement","volume":"200","author":"Graham","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020221021553300_bib9","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Multi-ethnic reference values for spirometry for the 3\u201395-yr age range: the global lung function 2012 equations","volume":"40","author":"Quanjer","year":"2012","journal-title":"Eur Respir J"},{"key":"2026020221021553300_bib10","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1183\/09031936.00069712","article-title":"Consensus statement for inert gas washout measurement using multiple- and single- breath tests","volume":"41","author":"Robinson","year":"2013","journal-title":"Eur Respir J"},{"key":"2026020221021553300_bib11","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1513\/AnnalsATS.201501-021FR","article-title":"Multiple-breath washout as a lung function test in cystic fibrosis: a Cystic Fibrosis Foundation workshop report","volume":"12","author":"Subbarao","year":"2015","journal-title":"Ann Am Thorac Soc"},{"key":"2026020221021553300_bib12","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1164\/rccm.201801-0074ST","article-title":"Preschool multiple-breath washout testing: an official American Thoracic Society technical statement","volume":"197","author":"Robinson","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020221021553300_bib13","article-title":"CDC growth charts data files","author":"Centers for Disease Control and Prevention, National Center for Health Statistics","year":"2024"},{"key":"2026020221021553300_bib14","doi-asserted-by":"crossref","first-page":"e0021521","DOI":"10.1128\/cmr.00215-21","article-title":"Practical guidance for clinical microbiology laboratories: updated guidance for processing respiratory tract samples from people with cystic fibrosis","volume":"37","author":"Saiman","year":"2024","journal-title":"Clin Microbiol Rev"},{"key":"2026020221021553300_bib15","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1086\/318075","article-title":"Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis","volume":"183","author":"Burns","year":"2001","journal-title":"J Infect Dis"},{"key":"2026020221021553300_bib16","doi-asserted-by":"crossref","first-page":"e167957","DOI":"10.1172\/JCI167957","article-title":"Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist","volume":"133","author":"Nichols","year":"2023","journal-title":"J Clin Invest"},{"key":"2026020221021553300_bib17","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1136\/thoraxjnl-2021-218347","article-title":"Evaluation of clinically relevant changes in the lung clearance index in children with cystic fibrosis and healthy controls","volume":"78","author":"Perrem","year":"2023","journal-title":"Thorax"},{"key":"2026020221021553300_bib18","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2307\/1942268","article-title":"An ordination of the upland forest communities of southern Wisconsin","volume":"27","author":"Bray","year":"1957","journal-title":"Ecol Monogr"},{"key":"2026020221021553300_bib19","doi-asserted-by":"crossref","first-page":"e184171","DOI":"10.1172\/JCI184171","article-title":"Elexacaftor\/tezacaftor\/ivacaftor\u2019s effects on cystic fibrosis infections are maintained, but not increased, after 3.5 years of treatment","volume":"134","author":"Morgan","year":"2024","journal-title":"J Clin Invest"},{"key":"2026020221021553300_bib20","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jcf.2023.10.010","article-title":"Effect of elexacaftor\/tezacaftor\/ivacaftor on mucus and mucociliary clearance in cystic fibrosis","volume":"23","author":"Donaldson","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2026020221021553300_bib21","doi-asserted-by":"crossref","first-page":"L432","DOI":"10.1152\/ajplung.00461.2017","article-title":"Lumacaftor (VX-809) restores the ability of CF macrophages to phagocytose and kill Pseudomonas aeruginosa","volume":"314","author":"Barnaby","year":"2018","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2026020221021553300_bib22","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1164\/rccm.202106-1426OC","article-title":"Trikafta rescues CFTR and lowers monocyte P2X7R-induced inflammasome activation in cystic fibrosis","volume":"205","author":"Gabillard-Lefort","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020221021553300_bib23","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1164\/rccm.202308-1317OC","article-title":"Improvement in lung clearance index and chest computed tomography scores with elexacaftor\/tezacaftor\/ivacaftor treatment in people with cystic fibrosis aged 12 years and older\u2014the RECOVER trial","volume":"208","author":"McNally","year":"2023","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/22\/11\/1696\/66620653\/annalsats_22_11_1696.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/22\/11\/1696\/66620653\/annalsats_22_11_1696.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T02:02:26Z","timestamp":1770084146000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/22\/11\/1696\/8444090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":23,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,1]]},"published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.202501-103oc","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,11,1]]},"assertion":[{"value":"2025-01-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}